(Q33376938)

English

Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Intensified dose of cyclophosphamide with G-CSF support versus standard dose combined with platinum in first-line treatment of advanced ovarian cancer a randomised study from the GINECO group (English)

1 reference

Europe PubMed Central

26 July 2017

1 reference

based on heuristic

inferred from title

Isabelle Ray-Coquard

1

object named as

I Ray-Coquard

0 references

author name string

D Paraiso

2

1 reference

Europe PubMed Central

26 July 2017

J-P Guastalla

3

1 reference

Europe PubMed Central

26 July 2017

B Leduc

4

1 reference

Europe PubMed Central

26 July 2017

F Guichard

5

1 reference

Europe PubMed Central

26 July 2017

C Martin

6

1 reference

Europe PubMed Central

26 July 2017

L Chauvenet

7

1 reference

Europe PubMed Central

26 July 2017

Z Haddad-Guichard

8

1 reference

Europe PubMed Central

26 July 2017

D Lepillé

9

1 reference

Europe PubMed Central

26 July 2017

H Orfeuvre

10

1 reference

Europe PubMed Central

26 July 2017

H Gautier

11

1 reference

Europe PubMed Central

26 July 2017

D Castera

12

1 reference

Europe PubMed Central

26 July 2017

E Pujade-Lauraine

13

1 reference

Europe PubMed Central

26 July 2017

language of work or name

0 references

publication date

9 October 2007

1 reference

Europe PubMed Central

26 July 2017

British Journal of Cancer

1 reference

Europe PubMed Central

26 July 2017

97

1 reference

Europe PubMed Central

26 July 2017

9

1 reference

Europe PubMed Central

26 July 2017

1200-1205

1 reference

Europe PubMed Central

26 July 2017

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6604026

0 references

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360456

21 June 2018

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360456

21 June 2018

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360456

21 June 2018

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360456

21 June 2018

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360456

21 June 2018

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360456

21 June 2018

Options for primary chemotherapy of epithelial ovarian cancer: taxanes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360456

21 June 2018

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360456

21 June 2018

Chemotherapy of ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2360456

21 June 2018

Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604026

21 January 2018

Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis

1 reference

https://pubmed.ncbi.nlm.nih.gov/17923867

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs. cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5

1 reference

https://pubmed.ncbi.nlm.nih.gov/17923867

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/17923867

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/17923867

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/17923867

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6604026

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.BJC.6604026

1 reference

Europe PubMed Central

26 July 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33376938&oldid=1975523860"